DNA, Peptide Vaccines Advance Against GBM.
- In the news
DNA-based GNOS-PV01 and peptide-based NeoVax show promise as personalized vaccines for glioblastoma, with GNOS-PV01 effective against the challenging MGMT-unmethylated subtype.
- Why it matters: Glioblastoma, especially the MGMT-unmethylated subtype, has limited treatment options and poor prognosis, highlighting the need for innovative therapies.
- What they did: Researchers conducted a Phase I trial testing two personalized vaccine strategies—DNA-based GNOS-PV01 and peptide-based NeoVax—in glioblastoma patients.
- The result: Findings suggest both vaccines are promising, with GNOS-PV01 notably effective against the difficult-to-treat MGMT-unmethylated glioblastoma, potentially improving outcomes for this subgroup.